South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Graphite Bio is raising $150,749,985.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Josh Lehrer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Graphite Bio

At Graphite Bio, we are rapidly building a next-generation gene editing company that is driven to apply our breakthrough technology with urgency to advance gene replacement therapies and cures for people living with serious diseases. We stand apart through our ability to harness natural and highly precise cellular DNA repair machinery to achieve high efficiency, targeted gene integration to correct the underlying causes of diseases. Our highly-differentiated, targeted gene integration platform harnesses CRISPR and natural DNA repair processes called homology directed repair (HDR) to precisely replace a damaged portion of a gene or insert new genetic information to treat disease. We are working with urgency to apply the unique capabilities of our platform to deliver gene replacement therapies that offer one-time outpatient cures across a range of genetic and other diseases.

To learn more about Graphite Bio, visit http://graphitebio.com/

Contact:
Josh Lehrer, Chief Executive Officer
650-484-0886
https://www.linkedin.com/in/josh-lehrer-8b33199/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved